DAWN
Day One Biopharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.53
+0.00%Year over year
Reported trailing growth
- Revenue
- +20.6%
- EBITDA
- -34.1%
- EBIT
- +41.2%
- EPS
- +4.6%
- Free cash flow
- +29.4%
- Operating cash flow
- -32.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +20.6%
- EBITDA
- +42.4%
- EBIT
- +41.2%
- Net income
- -12.4%
- EPS
- -2.0%
- Free cash flow
- -29.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025